BI-1206
Based on 1 Customer Validation
BI-1206 is a recombinant and antagonistic human monoclonal antibody targeting FcγRIIB (CD32B). BI-1206 can block CD20 internalization induced by Rituximab (HY-P9913) itself or combined with others including Ibrutinib (HY-10997), Venetoclax (HY-15531), and CHOP. BI-1206 can enhance or recover the activity of Rituximab or other anti-CD20 monoclonal antibodies. BI-1206 has cytolytic activity against malignant B cells. BI-1206 can be studied for cancer research such as mantle cell lymphoma (MCL).
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 96.82%
- 분자량:143.68 kDa
-
보관:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- 순도&문서
- References
-
Help & FAQs
Biological Activity
제품 설명
Isotype
Human IgG1 lambda
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
Fc gamma RIIB/CD32b
In Vitro
BI-1206 (5 μg/mL, 0-5 h) blocks Rituximab (5 μg/mL)-induced and Rituximab-based combination with Ibrutinib or Venetoclax or CHOP-induced CD20 internalization effectively in JeKo-1 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
BI-1206 (10 mg/kg, i.v., twice a week) inhibits tumor growth when combined with Rituximab in Rituximab-Ibrutinib-CAR T-triple resistant MCL PDX (PDX-B) NSG mice model[1].
BI-1206 (10 mg/kg, i.v., twice a week for 14 d) has better efficacy and prolonged survival in the triple combination group with Ibrutinib or Venetoclax compared to dual combinations without BI-1206 in JeKo-1 CDX mice model[1].
BI-1206 (10 mg/kg, i.v., twice a week) shows superior anti-tumor activity and prolonged survival when combined with Venetoclax compared to any single or dual combination in Ibrutinib-Rituximab-Venetoclax triple-resistant MCL PDX (PDX-C) model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Ibrutinib-Venetoclax dual resistant MCL PDX (PDX-A) NSG mice model[1]
-
Dosage:10 mg/kg, twice a week
-
Administration:Intravenous injection (i.v.)
-
Result:Reduced percentage of MCL tumor cells (CD5+CD20+) in spleen, liver, bone marrow, and peripheral blood collected from PDX-A mice model.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
신청
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized hu-Fcgamma RIIB/C (CD32b/c)-C-his can bind BI-1206. The EC50 for this effect is 27.61 ng/mL.
Chemical Information
-
Appearance Liquid
-
분자량 143.68 kDa
-
Color Colorless to off-white
-
SMILES
[BI-1206]
-
선적
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
-
Data Sheet (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
BI-1206 Related Classifications
HY-P991225 Related Classifications
Powered by Bioz